You are here

P&T November 2013

Features

Products containing omega-3 fatty acids, such as krill oil and fish oils, have been effective in lowering triglyceride levels. Although no data have suggested that the low-density lipoprotein-cholesterol (LDL-C) increases associated with some omega-3 fatty acid formulations lead to adverse outcomes, these elevations in LDL-C levels may compromise the achievement of lipid targets. Thus, there is a need for agents that can lower triglyceride levels without increasing LDL-C levels.
Managing hemorrhaging after the use of warfarin and other anticoagulants is challenging. Although an FDA-approved product, FEIBA, has been used as an off-label anticoagulant-reversal agent, the potential risks of thrombosis associated with activated prothrombin complex concentrates must be carefully weighed.
Hospital Pharmacies Could Face New Pressures
With the Patient Protection and Affordable Care Act going into effect in 2014, hospitals are scrambling to ensure that their formularies meet federal standards.
Meeting Highlights
Therapies for breast cancer, melanoma, lung cancer, and neuroendocrine tumors

Departments

Prescription: Washington
Stricter labeling requirements for ER and LA opioids might not be enough.
Medication Errors

Avoiding dangerous lapses in infection-control practices

Drug Forecast
Canagliflozin (Invokana) for type-2 diabetes

FDA approvals, drug indications, and updates

Vortioxetine (Brintellix) for major depressive disorder; ustekinumab (stelara) for psoriatic arthritis; and dabrafenib mesylate (Tafinlar) for metastatic melanoma